Clinical Trial Update: Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating stereotactic body radiation therapy combined with anti-PD-1 antibody in patients with hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anti-PD-1 antibody
• Stereotactic Body Radiation Therapy (SBRT)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN